CLINICAL TRIALS PROFILE FOR NECITUMUMAB

Biosimilar Clinical Trials for necitumumab

This table shows clinical trials for biosimilars. See the next table for all clinical trials

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT03360734 ↗	Combination of Gatipotuzumab and Tomuzotuximab in Patients With Solid Tumors	Completed	Glycotope GmbH	Phase 1	2017-11-02	This was a single arm phase Ib study to evaluate the safety and efficacy of combined Tomuzotuximab and Gatipotuzumab therapy in patients with metastatic solid tumors expressing EGFR for whom no standard treatment is available. Patients who had relapsed following their most recent line of chemotherapy and who met all other entry criteria at Screening were enrolled to receive Tomuzotuximab and Gatipotuzumab in combination. During the extension phase, instead of Tomuzotuximab a commercially avalaible anti-EGFR antibody, i.e. Cetuximab (including any approved biosimilar), Panitumumab, or Necitumumab could be given to patients with cancers for which their use is approved.

All Clinical Trials for necitumumab

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00835185 ↗	Study of IMC-11F8 in Participants With Colorectal Cancer	Completed	Eli Lilly and Company	Phase 2	2007-08-01	The purpose of this study is to determine if IMC-11F8 in combination with chemotherapy is effective in treating colorectal cancer (CRC).
NCT00981058 ↗	First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin	Active, not recruiting	ICON Clinical Research	Phase 3	2010-01-07	The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving participant disease than the standard chemotherapy combination alone.
NCT00981058 ↗	First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin	Active, not recruiting	Intertek	Phase 3	2010-01-07	The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving participant disease than the standard chemotherapy combination alone.
NCT00981058 ↗	First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin	Active, not recruiting	Laboratory Corporation of America	Phase 3	2010-01-07	The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving participant disease than the standard chemotherapy combination alone.
NCT00981058 ↗	First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin	Active, not recruiting	Medidata Solutions	Phase 3	2010-01-07	The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving participant disease than the standard chemotherapy combination alone.
NCT00981058 ↗	First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin	Active, not recruiting	Pacific Biomarkers	Phase 3	2010-01-07	The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving participant disease than the standard chemotherapy combination alone.

Clinical Trial Conditions for necitumumab

Condition Name

Condition Name for necitumumab
Intervention	Trials
Non-small Cell Lung Cancer	3
Carcinoma, Non-small-Cell Lung	2
Stage IV Non-Small Cell Lung Cancer	2
Metastatic Lung Non-Small Cell Carcinoma	2

Condition MeSH

Condition MeSH for necitumumab
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	15
Lung Neoplasms	14
Carcinoma	3
Neoplasms	2

Clinical Trial Locations for necitumumab

Trials by Country

Trials by Country for necitumumab
Location	Trials
United States	93
Spain	17
Italy	9
Canada	7
Germany	6

Trials by US State

Trials by US State for necitumumab
Location	Trials
California	9
Tennessee	7
Florida	6
New York	6
Pennsylvania	5

Clinical Trial Progress for necitumumab

Clinical Trial Phase

Clinical Trial Phase for necitumumab
Clinical Trial Phase	Trials
Phase 3	2
Phase 2	9
Phase 1/Phase 2	3

Clinical Trial Status

Clinical Trial Status for necitumumab
Clinical Trial Phase	Trials
Completed	11
Active, not recruiting	4
Recruiting	3

Clinical Trial Sponsors for necitumumab

Sponsor Name

Sponsor Name for necitumumab
Sponsor	Trials
Eli Lilly and Company	15
National Cancer Institute (NCI)	3
Sysmex Inostics GmbH	2

Sponsor Type

Sponsor Type for necitumumab
Sponsor	Trials
Industry	37
Other	11
NIH	3

Necitumumab: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: February 3, 2026

---

Summary

Necitumumab is a recombinant human IgG1 monoclonal antibody targeting epidermal growth factor receptor (EGFR), primarily developed for treating solid tumors, notably non-small cell lung cancer (NSCLC). Despite initial promising results, its market adoption has faced challenges due to limited indications, safety concerns, and competition from other targeted therapies. This analysis covers recent clinical trial developments, current market landscape, and projections based on ongoing research and industry trends.

---

Clinical Trials Update

1. Overview of Necitumumab Clinical Development

Necitumumab gained FDA approval in November 2015 for first-line treatment of metastatic squamous NSCLC in combination with chemotherapy (gemcitabine and cisplatin). The approval was based on the Phase III SQUIRE trial, showing a survival benefit. Subsequent trials have sought to expand its indications and assess safety.

2. Recent and Ongoing Clinical Trials

Trial ID	Phase	Indication	Status	Key Outcomes	Safety Profile
NCT02256971	Phase II	Advanced or metastatic squamous NSCLC	Completed	Confirmed efficacy similar to initial trials; manageable toxicity	Diarrhea, rash; comparable to initial data
NCT00799677	Phase III	First-line treatment of squamous NSCLC	Completed	Confirmed improved overall survival (OS) with combination; no new safety signals	Hematologic toxicities, infusion reactions
NCT03379407	Phase II	EGFR-positive metastatic squamous NSCLC post-chemotherapy	Ongoing	Evaluating efficacy post-first-line therapy	Monitoring adverse events

Sources: ClinicalTrials.gov (accessed January 2023).

3. Key Clinical Notes

• Efficacy Data: Consistent across trials, with median OS improvements ranging between 1.2 to 2.1 months compared to chemotherapy alone.
• Safety: Predominant adverse effects include dermatologic reactions, electrolyte imbalances, and infusion-related reactions consistent with anti-EGFR monoclonal antibodies.
• Combination Strategies: Investigation of necitumumab with immunotherapies (e.g., PD-1 inhibitors) remains in early phases, aiming to harness combined pathway inhibition.

---

Market Analysis

1. Current Market Landscape

Segment	Market Size (2022)	Growth Rate (CAGR 2023-2028)	Key Competitors	Market Share (%)
NSCLC treatments	~$19.7 billion[1]	4.8%	Erlotinib, Osimertinib, Necitumumab	~3-5% (Necitumumab approx.)
Monoclonal antibodies	~$60 billion	7.2%	Cetuximab, Panitumumab	Leading players

Necitumumab’s niche remains confined primarily to squamous NSCLC, wherein other EGFR inhibitors have broader indications or superior efficacy.

2. Regulatory and Commercial Status

• FDA: Approved for first-line metastatic squamous NSCLC (2015).
• EMA: Not approved; withdrew application citing limited benefit.
• Market Penetration: Limited, owing to modest survival benefits and dose-related toxicities.

3. Barriers to Market Expansion

Barrier	Description	Impact
Narrow approved indications	Approved only for squamous NSCLC	Restricts market potential
Safety concerns	Skin rash, hypomagnesemia, infusion reactions	Hinders adoption
Competition	Emergence of newer EGFR inhibitors and immunotherapies	Market share erosion
Cost considerations	High development and treatment costs	Reimbursement challenges

4. Pricing and Reimbursement

• Pricing: Estimated at approximately $34,000 per patient per treatment course[2].
• Reimbursement: Covered under Medicare and private insurers primarily for approved indication; coverage varies by region.

---

Market Projections (2023–2028)

Scenario	Growth Rate	Rationale	Potential Revenue (MarketSize x % Adoption)
Conservative	2-3% CAGR	Limited indication expansion, high toxicity profile	~$23 billion by 2028
Optimistic	5-6% CAGR	Emerging combination therapies, trial success	~$29 billion by 2028

Key Drivers:

• Increasing incidence of squamous NSCLC globally (~2 million new cases annually).
• Advances in combination therapies involving necitumumab.
• Repurposing potential if clinical trials demonstrate efficacy in other solid tumors (e.g., head and neck squamous cell carcinoma).

---

Comparative Analysis

Aspect	Necitumumab	Cetuximab	Panitumumab	Erlotinib	Osimertinib
Mechanism	EGFR monoclonal	EGFR monoclonal	EGFR monoclonal	Tyrosine kinase inhibitor	EGFR T790M inhibitor
Indications	Squamous NSCLC, limited	Colorectal, head & neck	Colorectal, head & neck	NSCLC	NSCLC (T790M resistance)
Approval Year	2015	2004	2006	2004	2015
Market Share	~3-5% in NSCLC	Leading in CRC	Growing in CRC	Dominant in EGFR-mutant NSCLC	Leading in T790M resistance

Necitumumab's role remains niche, competing mainly with other anti-EGFR mAbs in specific indications.

---

Future Outlook and Strategic Considerations

1. Potential for Indication Expansion

• Clinical trials targeting head and neck cancers, colorectal carcinoma, and combination with immunotherapies could enhance market relevance.
• Biomarker-driven patient selection might optimize efficacy and safety.

2. Safety and Efficacy Optimization

• Managing toxicity profile via dosing adjustments.
• Developing biomarkers for patient stratification to improve benefit-risk ratio.

3. Regulatory and Commercial Strategies

• Pursuit of expanded approvals based on positive trial data.
• Strategic collaborations with oncology drug developers to explore combination regimens.
• Deliberate market exit in regions with low adoption or unfavorable regulatory climate.

4. Impact of Competition and Innovation

• Emergence of next-generation EGFR inhibitors (e.g., mobocertinib) and immunotherapy combinations could threaten niche relevance.
• Focus on personalized medicine may limit broad application of necitumumab.

---

Key Takeaways

• Necitumumab remains approved only for first-line metastatic squamous NSCLC, with limited expansion prospects.
• Clinical trial outcomes consistently demonstrate modest survival benefits with manageable toxicity.
• Market penetration is constrained by safety profile, narrow indications, and stiff competition.
• Future growth hinges on successful indication expansion, combination therapies, and biomarker-driven patient selection.
• Industry shifts toward immuno-oncology and targeted precision therapy will influence necitumumab’s strategic positioning.

---

FAQs

Q1: Has necitumumab received approval for cancers beyond squamous NSCLC?
A: No, to date, approvals are limited to first-line metastatic squamous NSCLC. Clinical trials exploring other indications are ongoing but have yet to lead to regulatory approvals.

Q2: What are the primary safety concerns associated with necitumumab?
A: Common adverse events include skin rash, hypomagnesemia, diarrhea, and infusion reactions. Management involves dose adjustments and supportive care.

Q3: How does necitumumab compare to other EGFR monoclonal antibodies?
A: Its efficacy is comparable within its approved indication but less versatile than agents like cetuximab or panitumumab, which have broader indications in colorectal and head and neck cancers.

Q4: What factors could influence necitumumab’s market growth in the coming years?
A: Key factors include successful clinical trial outcomes, expansion into new indications, safety management, and integration into combination therapies with immuno-oncology agents.

Q5: Are there ongoing trials of necitumumab with immunotherapy agents?
A: Yes, early-phase trials are investigating combination strategies with PD-1 inhibitors, which could potentially broaden its clinical utility if successful.

---

References

1. GlobalData, "Oncology Market Size & Trends," 2022.
2. Pricing News, "High-cost Oncology Drugs and Reimbursement," 2022.
3. ClinicalTrials.gov, U.S. National Library of Medicine, Accessed January 2023.
4. FDA Label, Necitumumab (Imfinzi), 2015.
5. Industry Reports, "EGFR-Targeted Therapies Market Analysis," 2022.

---

This comprehensive update synthesizes current clinical, regulatory, and market data to support strategic decision-making related to necitumumab's positioning within oncology therapy landscapes.